300 related articles for article (PubMed ID: 18946748)
1. Safety profiles of aromatase inhibitors and selective estrogen-receptor modulators in the treatment of early breast cancer.
Yamamoto Y; Iwase H
Int J Clin Oncol; 2008 Oct; 13(5):384-94. PubMed ID: 18946748
[TBL] [Abstract][Full Text] [Related]
2. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective.
Conte P; Frassoldati A
Breast J; 2007; 13(1):28-35. PubMed ID: 17214790
[TBL] [Abstract][Full Text] [Related]
3. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer.
Perez EA
Ann Oncol; 2007 Sep; 18 Suppl 8():viii26-35. PubMed ID: 17890211
[TBL] [Abstract][Full Text] [Related]
4. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
Gradishar WJ
Oncology; 2005; 69(1):1-9. PubMed ID: 16088229
[TBL] [Abstract][Full Text] [Related]
5. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
Mouridsen HT
Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
[TBL] [Abstract][Full Text] [Related]
6. Long-term toxicities of selective estrogen-receptor modulators and antiaromatase agents.
Mortimer JE; Urban JH
Oncology (Williston Park); 2003 May; 17(5):652-9; discussion 659, 662, 666 passim. PubMed ID: 12800793
[TBL] [Abstract][Full Text] [Related]
7. Clinical review: Effect of endocrine therapies on bone in breast cancer patients.
Santen RJ
J Clin Endocrinol Metab; 2011 Feb; 96(2):308-19. PubMed ID: 21147884
[TBL] [Abstract][Full Text] [Related]
8. Vascular effects of aromatase inhibitors: data from clinical trials.
Howell A; Cuzick J
J Steroid Biochem Mol Biol; 2005 May; 95(1-5):143-9. PubMed ID: 15936188
[TBL] [Abstract][Full Text] [Related]
9. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
10. Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective.
Garreau JR; Delamelena T; Walts D; Karamlou K; Johnson N
Am J Surg; 2006 Oct; 192(4):496-8. PubMed ID: 16978958
[TBL] [Abstract][Full Text] [Related]
11. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
Berry J
Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
[TBL] [Abstract][Full Text] [Related]
12. Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - Meta-analyses on efficacy and adverse events based on randomized clinical trials.
Rydén L; Heibert Arnlind M; Vitols S; Höistad M; Ahlgren J
Breast; 2016 Apr; 26():106-14. PubMed ID: 27017249
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant trials of aromatase inhibitors: determining the future landscape of adjuvant endocrine therapy.
Ragaz J
J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):133-41. PubMed ID: 11850217
[TBL] [Abstract][Full Text] [Related]
14. Postmenopausal women with hormone receptor-positive breast cancer: balancing benefit and toxicity from aromatase inhibitors.
Ingle JN
Breast; 2013 Aug; 22 Suppl 2():S180-3. PubMed ID: 24074784
[TBL] [Abstract][Full Text] [Related]
15. Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors.
Mincey BA; Duh MS; Thomas SK; Moyneur E; Marynchencko M; Boyce SP; Mallett D; Perez EA
Clin Breast Cancer; 2006 Jun; 7(2):127-32. PubMed ID: 16800971
[TBL] [Abstract][Full Text] [Related]
16. Aromatase inhibitors and mood disturbances.
Rocha-Cadman X; Massie MJ; Du Hamel K
Palliat Support Care; 2012 Sep; 10(3):225-7. PubMed ID: 22677000
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of adverse events of endocrine therapies among older patients with breast cancer.
Honma N; Makita M; Saji S; Mikami T; Ogata H; Horii R; Akiyama F; Iwase T; Ohno S
Support Care Cancer; 2019 Oct; 27(10):3813-3822. PubMed ID: 30729298
[TBL] [Abstract][Full Text] [Related]
18. Are aromatase inhibitors superior to antiestrogens?
Howell A; Buzdar A
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):237-47. PubMed ID: 15860266
[TBL] [Abstract][Full Text] [Related]
19. A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer.
McCaig FM; Renshaw L; Williams L; Young O; Murray J; Macaskill EJ; McHugh M; Hannon R; Dixon JM
Breast Cancer Res Treat; 2010 Feb; 119(3):643-51. PubMed ID: 19941160
[TBL] [Abstract][Full Text] [Related]
20. [Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
de Cremoux P; Diéras V; Poupon MF; Magdelénat H; Sigal-Zafrani B; Fourquet A; Pierga JY
Bull Cancer; 2004 Dec; 91(12):917-27. PubMed ID: 15634633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
